The landscape of dementia diagnosis has progressed dramatically with the arrival of subtle biomarkers, including amyloid PET scans, tau imaging, and blood-dependent assessments which can detect Alzheimer's pathology decades before indications emerge. Whilst these technological developments signify remarkable progress in knowledge neurodegenerative